Kidney Cancer
@intkidneycancer
We talk about research, studies, trials, therapies, medical doctors and specialist centers in the world. WE WANT TO GIVE CONCRETE SUPPORT TO PATIENTS
ID: 1827609221187145729
https://www.facebook.com/profile.php?id=61558060540685 25-08-2024 07:29:48
134 Tweet
105 Takipçi
656 Takip Edilen
🚀 Now enrolling MD Anderson Cancer Center: IVORY trial of #ivonescimab (first-in-class PD1×VEGF bispecific) in metastatic clear cell #KidneyCancer after prior IO±TKI. Hypothesis: cooperative inhibition of PD1/VEGF signaling will restore treatment sensitivity 👉 clinicaltrials.gov/study/NCT06940…
1/ New review on Chromophobe Renal Cell Carcinoma (ChRCC) detailing its distinct features, current management regimens, ongoing trials, and future biology-tailored treatments. Michel AlChoueiry Wenxin (Vincent) Xu Lisa Henske 🧵below: doi.org/10.1016/j.crit…
RWD SARCOMATOIDE en Ca renal En @asco JCO Global Oncology 🔴 350 pacietes IO+IO o IO+TKI en 1ª linea 🟠 19m seguimiento & mOS 26.9 🟢 IMDC Favorable 66.5 Inter 29.6m Pobre 11.7m 🔵 Comparación COMBOS Felicidades ARON project y colaboradores Francesco Massari Enrique Grande Fernando Sabino, MD, PhD
The final analysis of cabozantinib plus nivolumab in 1st line clear cell renal cancer Annals of Oncology Toni Choueiri, MD shows consistent data over time and with other VEGF/PD-1 combinations. ‘Pick one and use it well’ remains a good approach.
KIM-1 is the hottest biomarker in kidney cancer. Some call it the ctDNA of this disease. Wenxin (Vincent) Xu leads the research in this area. In this video he defines positivity & tells us what that means. Is it ready for clinical use VIncent ? OncoAlert Toni Choueiri, MD #UromigosLive
Here's our latest - a deep dive into myeloid mediated immunotherapy resistance in kidney cancer, pairing single cell meta-analysis with companion experiments (h/t Toni Choueiri, MD + David Braun collaborations) Congrats Kevin Bi et al! Dana-Farber Broad Institute Immunity
Another Eli Van Allen Dana-Farber Lank Center for Genitourinary Oncology collaboration with our friend David Braun + many super stars like Chris Labaki Eddy Saad Ziad Bakouny, MD, MSc et al (all co-mentored Eli Van Allen)--we will unlock biomarkers of IO resistance in RCC, 1 step at a time. cc: Dana-Farber Lank Center for Genitourinary Oncology Immunity
Understanding ICI resistance will be key to next wave of effective treatments in refractory #kidneycancer. Great work Eli Van Allen David Braun Toni Choueiri, MD et al!
In this video Wenxin (Vincent) Xu gives an overview on the most promising biomarker to date in kidney cancer (KIM1). In the CAPLPSO clear cell trial more KIM-1 ⬇️ occurred with durva/treme vs Durva alone. Could KIM1 be better surrogate of OS than radiology. Toni Choueiri, MD OncoAlert
Papillary RCC has become better studied in the last decade, but still lacks definitive data. Aly-Khan Lalani masterfully reviews this topic. He may also win best dressed among the videos 😀
KIM-1 biomarker data from adjuvant immunotherapy trials in #RenalCellCarcinoma. Wenxin (Vincent) Xu Dana-Farber joins Pedro C Barata, MD MSc FACP Case Comp Cancer Ctr to discuss this emerging biomarker in #RCC. Dr. Xu explains that KIM-1 is highly upregulated in proximal tubule kidney tumors and can be detected
ARTICLE INSIGHTS! Thank you Phillip Pierorazio for your insights into, "Risk Factors for First-Year Recurrence in Patients With Synchronous Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy and Complete Metastasectomy." 🔗 Read more: bit.ly/3WlGrF1
UROwebinar Alert Locally advanced renal cancer – Surgical challenges 📅 11 Nov 25 🕢 18:30 Top faculty from ESU, EAU & YAU will cover complex RCC surgery, caval thrombus management, and the role of neo/adjuvant therapy 🔗 Register via MyEAU European School of Urology (EAU ESU)
Just out! Patients who permanently discontinue immunotherapy treatment, due to SirAE, after completing at least 3 months, have the same OS as patients who continue treatment continuously! This is the largest RWE study in this RCC setting! Congrats to ARON! onlinelibrary.wiley.com/doi/10.1002/ij…
🌟💛 Day 0 – #UromigosLIVE Pre-Meeting Coverage 🎬 From biomarker to storyteller: KIM-1 traces the natural history of kidney cancer.🌟 Fascinating #UromigosShorts by Dr. Vincent Xu, exploring how KIM-1 may redefine prognosis and response prediction in RCC 🔬 Wenxin (Vincent) Xu
Advancing the management of indeterminate renal masses: The emerging role of molecular imaging. Alexander Kutikov MD Fox Chase Cancer Center joins Zach Klaassen Georgia Cancer Center in this conversation, highlighting exciting developments in molecular imaging, particularly the #ZIRCON trial's TLX250